Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives

Research output: Contribution to journalReview articlepeer-review

Standard

Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives. / Jayash, Soher; Al-Namnam, Nisreen Mohammed ; Shaghayegh, Gohar .

In: Biointerface Research in Applied Chemistry, Vol. 10, No. 2, 03.02.2020, p. 5193-5200.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Jayash, Soher ; Al-Namnam, Nisreen Mohammed ; Shaghayegh, Gohar . / Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives. In: Biointerface Research in Applied Chemistry. 2020 ; Vol. 10, No. 2. pp. 5193-5200.

Bibtex

@article{732fed20244142a4a4c2f68671188ccb,
title = "Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives",
abstract = "Remodeling process results from the action of the tissue-forming osteoblasts and the tissue-resorbing osteoclasts which work together in certain cell units called basic multicellular units (BMUs). The local regulation of the bone cell function includes the receptor activator of nuclear factor κB ligand (RANKL)/ receptor activator of nuclear factor κB (RANK) / Osteoprotegerin (OPG) system. These molecules are key factors linking bone formation to resorption during the bone remodeling process. The OPG/RANKL/RANK system has a role in the pathogenesis of bone loss by modulating RANK-induced osteoclastogenesis. This role has provided the rationale for durg development that treat the bone diseases. Systemic OPG therapy was used for bone disease treatment parenteral. According to our knowledge that got from researches, there is no study has been done to explore the use of the local delivery system of OPG in the bone resorption treatment. This approach may have similar osteogenic potential in bone defects that might be capable of treatment the bone loss. ",
keywords = "Osteoprotegerin, Bone Remodeling, bone diseases, Bone diseases, Bone remodeling",
author = "Soher Jayash and Al-Namnam, {Nisreen Mohammed} and Gohar Shaghayegh",
year = "2020",
month = feb,
day = "3",
doi = "10.33263/BRIAC102.193200",
language = "English",
volume = "10",
pages = "5193--5200",
journal = "Biointerface Research in Applied Chemistry",
issn = "5193-5200",
number = "2",

}

RIS

TY - JOUR

T1 - Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives

AU - Jayash, Soher

AU - Al-Namnam, Nisreen Mohammed

AU - Shaghayegh, Gohar

PY - 2020/2/3

Y1 - 2020/2/3

N2 - Remodeling process results from the action of the tissue-forming osteoblasts and the tissue-resorbing osteoclasts which work together in certain cell units called basic multicellular units (BMUs). The local regulation of the bone cell function includes the receptor activator of nuclear factor κB ligand (RANKL)/ receptor activator of nuclear factor κB (RANK) / Osteoprotegerin (OPG) system. These molecules are key factors linking bone formation to resorption during the bone remodeling process. The OPG/RANKL/RANK system has a role in the pathogenesis of bone loss by modulating RANK-induced osteoclastogenesis. This role has provided the rationale for durg development that treat the bone diseases. Systemic OPG therapy was used for bone disease treatment parenteral. According to our knowledge that got from researches, there is no study has been done to explore the use of the local delivery system of OPG in the bone resorption treatment. This approach may have similar osteogenic potential in bone defects that might be capable of treatment the bone loss.

AB - Remodeling process results from the action of the tissue-forming osteoblasts and the tissue-resorbing osteoclasts which work together in certain cell units called basic multicellular units (BMUs). The local regulation of the bone cell function includes the receptor activator of nuclear factor κB ligand (RANKL)/ receptor activator of nuclear factor κB (RANK) / Osteoprotegerin (OPG) system. These molecules are key factors linking bone formation to resorption during the bone remodeling process. The OPG/RANKL/RANK system has a role in the pathogenesis of bone loss by modulating RANK-induced osteoclastogenesis. This role has provided the rationale for durg development that treat the bone diseases. Systemic OPG therapy was used for bone disease treatment parenteral. According to our knowledge that got from researches, there is no study has been done to explore the use of the local delivery system of OPG in the bone resorption treatment. This approach may have similar osteogenic potential in bone defects that might be capable of treatment the bone loss.

KW - Osteoprotegerin

KW - Bone Remodeling

KW - bone diseases

KW - Bone diseases

KW - Bone remodeling

UR - http://www.scopus.com/inward/record.url?scp=85082564500&partnerID=8YFLogxK

U2 - 10.33263/BRIAC102.193200

DO - 10.33263/BRIAC102.193200

M3 - Review article

VL - 10

SP - 5193

EP - 5200

JO - Biointerface Research in Applied Chemistry

JF - Biointerface Research in Applied Chemistry

SN - 5193-5200

IS - 2

ER -